Research Analysts Offer Predictions for BSX FY2025 Earnings

Boston Scientific Corporation (NYSE:BSX - Free Report) - Equities researchers at Leerink Partnrs issued their FY2025 earnings estimates for Boston Scientific in a report released on Monday, June 16th. Leerink Partnrs analyst M. Kratky expects that the medical equipment provider will earn $2.93 per share for the year. Leerink Partnrs currently has a "Strong-Buy" rating on the stock. The consensus estimate for Boston Scientific's current full-year earnings is $2.85 per share. Leerink Partnrs also issued estimates for Boston Scientific's FY2028 earnings at $4.32 EPS and FY2029 earnings at $4.79 EPS.

A number of other research firms have also issued reports on BSX. Citigroup reaffirmed a "buy" rating and set a $125.00 target price (up previously from $119.00) on shares of Boston Scientific in a report on Thursday, May 22nd. Morgan Stanley boosted their price target on shares of Boston Scientific from $120.00 to $125.00 and gave the company an "overweight" rating in a research report on Friday, May 16th. Evercore ISI boosted their price target on shares of Boston Scientific from $110.00 to $112.00 and gave the company an "outperform" rating in a research report on Thursday, April 24th. Leerink Partners began coverage on shares of Boston Scientific in a research report on Monday. They set an "outperform" rating and a $118.00 price target on the stock. Finally, Barclays boosted their price target on shares of Boston Scientific from $118.00 to $125.00 and gave the company an "overweight" rating in a research report on Friday, April 25th. Twenty-two investment analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $116.09.

Boston Scientific Price Performance

Boston Scientific stock opened at $101.72 on Wednesday. Boston Scientific has a 52-week low of $71.88 and a 52-week high of $107.17. The firm has a market capitalization of $150.49 billion, a price-to-earnings ratio of 74.25, a PEG ratio of 2.62 and a beta of 0.68. The company has a fifty day simple moving average of $101.35 and a 200-day simple moving average of $98.89. The company has a quick ratio of 0.88, a current ratio of 1.45 and a debt-to-equity ratio of 0.47.

Boston Scientific (NYSE:BSX - Get Free Report) last released its earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.67 by $0.08. Boston Scientific had a net margin of 11.58% and a return on equity of 18.67%. The business had revenue of $4.66 billion during the quarter, compared to analyst estimates of $4.57 billion. During the same quarter in the prior year, the firm earned $0.56 earnings per share. The company's revenue for the quarter was up 20.9% compared to the same quarter last year.

Institutional Trading of Boston Scientific

Large investors have recently made changes to their positions in the company. Norges Bank purchased a new position in Boston Scientific in the fourth quarter valued at approximately $1,762,522,000. Capital World Investors increased its stake in Boston Scientific by 28.7% in the fourth quarter. Capital World Investors now owns 27,899,903 shares of the medical equipment provider's stock valued at $2,492,041,000 after purchasing an additional 6,216,199 shares during the last quarter. Wellington Management Group LLP increased its stake in Boston Scientific by 10.2% in the fourth quarter. Wellington Management Group LLP now owns 36,165,399 shares of the medical equipment provider's stock valued at $3,230,293,000 after purchasing an additional 3,344,571 shares during the last quarter. GAMMA Investing LLC increased its stake in Boston Scientific by 11,720.3% in the first quarter. GAMMA Investing LLC now owns 2,577,887 shares of the medical equipment provider's stock valued at $260,057,000 after purchasing an additional 2,556,078 shares during the last quarter. Finally, Axiom Investors LLC DE increased its stake in Boston Scientific by 208.2% in the fourth quarter. Axiom Investors LLC DE now owns 3,752,430 shares of the medical equipment provider's stock valued at $335,167,000 after purchasing an additional 2,535,007 shares during the last quarter. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Boston Scientific

In related news, EVP John Bradley Sorenson sold 4,572 shares of the company's stock in a transaction that occurred on Monday, May 5th. The shares were sold at an average price of $104.54, for a total transaction of $477,956.88. Following the sale, the executive vice president now directly owns 18,705 shares in the company, valued at approximately $1,955,420.70. This represents a 19.64% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Arthur C. Butcher sold 17,314 shares of the company's stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $102.06, for a total transaction of $1,767,066.84. Following the sale, the executive vice president now owns 22,235 shares in the company, valued at $2,269,304.10. The trade was a 43.78% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 411,970 shares of company stock valued at $42,406,693. 0.50% of the stock is currently owned by corporate insiders.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.